Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 ...

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...

Tirzepatide: A dual-acting medication that combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist actions. This dual mechanism further amplifies insulin secretion ...

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit versions. Zepbound will be sold for $399 to $549 a month, compared to a previous list price of $1,059.

Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market. But when the drug was declared to be in shortage in December that same ...

Any use of tirzepatide jumped to 12.3% of all GLM use by December 2023, while SGLT2 inhibitor and GLP-1 RA use rose from 14.5% to 24.4% and 19.5% to 28.5%, respectively, between January 2021 and ...

TORONTO, May 13, 2025 /CNW/ - Lilly Canada is pleased to announce that Mounjaro ® KwikPen ® (tirzepatide injection) is now available in Canada in all doses, offering a convenient treatment ...

The Indian market for anti-obesity drugs has seen exponential growth, surging from Rs 137 crore in 2020 to Rs 535 crore in 2024. Novo Nordisk’s Rybelsus, an oral semaglutide tablet launched in ...